Language in Primary Progressive Aphasia
Launched by NORTHWESTERN UNIVERSITY · Sep 26, 2007
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Language in Primary Progressive Aphasia," aims to better understand how language and brain function change in people diagnosed with primary progressive aphasia (PPA). PPA is a condition that affects a person's ability to speak and understand language over time. Researchers are looking for participants who are right-handed, native English speakers, and can see and hear well enough to follow conversations. To take part, individuals must be able to safely undergo an MRI scan, which is a type of imaging test that helps doctors see inside the brain.
If you or a loved one is interested in participating, you should know that the study is currently recruiting participants. The trial is open to all genders, and it specifically excludes anyone who is left-handed, has a fear of enclosed spaces (claustrophobia), or has other serious health issues that might affect their ability to continue in the study. Participants can expect to contribute to important research that could help improve understanding of PPA and potentially lead to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of primary progressive aphasia
- • Right-handed
- • Native English speaker
- • Visual acuity of 20/30 corrected
- • Adequate hearing to follow conversation
- • Safe for an MRI scan
- Exclusion Criteria:
- • Left-handedness
- • Claustrophobia
- • Presence of significant medical illness that initially or in the future could interfere with continued participation in the study
About Northwestern University
Northwestern University is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a robust infrastructure that supports interdisciplinary collaboration, Northwestern leverages its expertise in various fields, including medicine, engineering, and social sciences, to drive groundbreaking studies. The university is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and focus on participant safety. Through its Clinical Trials Office, Northwestern aims to translate scientific discoveries into effective therapies, ultimately enhancing health outcomes and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Marsel Mesulam, MD
Principal Investigator
Northwestern University Feinberg School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials